OncLive TV

Dr. Bekaii-Saab on Differences Between Regorafenib and TAS-102 in CRC

September 20th 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses regorafenib and TAS-102. In colorectal cancer.

Dr. Kelly on the Toxicity Profile in CheckMate-227 in NSCLC

September 20th 2016

Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the toxicity profile of the therapies used in the CheckMate-227 trial.

Dr. Finn on Recent Advances in the Treatment of Liver Cancer

September 20th 2016

Richard S. Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses both recent advances in the treatment of patients with liver cancer, as well as the future role that immunotherapy stands to have in this field.

Dr. Pusztai on Evolution of Treatment for HER2+ Breast Cancer

September 20th 2016

Lajos Pustzai, MD, DPhil, professor of Medicine (Medical Oncology), chief of Breast Medical Oncology, co-director, Yale Cancer Center Genetics, Genomics and Epigenetics Program, Yale Cancer Center, discusses how treatment for patients with HER2-positive breast cancer has evolved.

Biology of Bone Metastases in Patients With mCRPC

September 19th 2016

Conor Lynch, PhD, an associate professor of Tumor Biology at Moffitt Cancer Center, discusses the biology of bone metastases in patients with castration-resistant prostate cancer.

Dr. Luke Nordquist on the Impact of Additional Doses of Radium-223 in mCRPC

September 17th 2016

Luke Nordquist, MD, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses a prospective study looking at the impact of an additional 6 doses of radium-223 dichloride in patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases.

Dr. Frakes on Late Toxicities in HPV-Associated Oropharynx Squamous Cell Carcinoma

September 16th 2016

Jessica Frakes, MD, assistant member, Department of Radiation Oncology, Moffitt Cancer Center, discusses some of the late toxicities seen in patients with HPV-positive oropharynx squamous cell carcinoma.

Dr. Bekaii-Saab on Microsatellite Instability in Colorectal Cancer

September 16th 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses microsatellite instability in colorectal cancer.

Dr. Yardley on Emerging Agents in HER2-Positive Breast Cancer

September 15th 2016

Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses some of the emerging agents in HER2-positive breast cancer.

Dr. Dummer on Driver Mutations and Next Steps in Melanoma

September 15th 2016

Reinhard Dummer, MD, professor, Department of Dermatology, University of Zurich Hospital, discusses driver mutations and next steps in the treatment of patients with melanoma.

Dr. Liauw on RT Advancements in Prostate Cancer

September 15th 2016

Stanley Liauw, MD, associate professor at the University of Chicago Medicine, discusses the advancements in radiation therapy (RT) over the last several years, and how he has seen the treatment affect his patients.

Dr. Hak Choy on Radiation and Immunotherapy in Combination in Lung Cancer

September 15th 2016

Dr. Cynthia Ma on Immunotherapy in TNBC

September 15th 2016

Dr. Jakubowiak on Minimal Residual Disease in Multiple Myeloma

September 15th 2016

Andrzej Jakubowiak, MD, PhD, professor of Medicine, director, Myeloma Program, University of Chicago Medicine, discusses minimal residual disease in multiple myeloma.

Dr. Wolchok on the Safety Profile in CheckMate-067 in Melanoma

September 15th 2016

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Department of Medicine and Ludwig Center at Memorial Sloan Kettering Cancer Center, discusses the safety profile in the CheckMate-067 trial, which examined nivolumab combined with ipilimumab in treatment-naïve patients with advanced melanoma.

Dr. Neal Shore on Treatment of Elderly Patients With mCRPC

September 14th 2016

Dr. Ball on Eventual Role of Immunotherapy in Patients With RCC

September 14th 2016

Mark Ball, MD, chief urology resident, Johns Hopkins University School of Medicine, discusses the eventual role that immunotherapy will play in the treatment landscape of renal cell carcinoma (RCC), as well as patient selection to receive immunotherapy as a single agent or in combination.

Dr. Riess on ROS1 Fusions in Lung Cancer

September 14th 2016

Jonathan Riess, MD, assistant professor of Medicine, Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses ROS1 fusions in lung cancer.

Dr. O'Shaughnessy on Precision Medicine in Triple Negative Breast Cancer

September 14th 2016

Joyce O'Shaughnessy, MD, co-chair, breast cancer research, chair breast cancer at Baylor University Medical Center, discusses precision medicine in triple negative breast cancer.

Effects of Testosterone-Lowering Drugs in Patients With Prostate Cancer

September 13th 2016

Heather S. Jim, PhD, associate member in the Health Outcomes and Behavioral Department, Moffitt Cancer Center, discusses the effects of testosterone-lowering drugs used as a treatment for patients with prostate cancer.